Global CBD Product Market 2024–2033

Reports Description

According to Custom Market Insights (CMI ), the Global CBD Product Market was estimated at USD 3 billion in 2021 and is expected to reach USD 6.33 billion in 2022 and is anticipated to reach around USD 33 billion by 2030, growing at a CAGR of roughly 11% between 2022 and 2030.

CMI research report offers a 360-degree view of the CBD Product market’s drivers and restraints, coupled with the impact they have on demand during the projection period. Also, the report examines global opportunities and competitive analysis for the CBD Product market.

To learn more about this report - request a sample report PDF

• Because hemp naturally contains a lot of cannabidiol (CBD), a chemical molecule found in the cannabis Sativa plant, hemp is the most common source of cannabidiol for extraction purposes. In addition to treating anxiety and seizures, it also lessens discomfort. The primary factor influencing the CBD product market is the increased demand for CBD for health and wellness purposes because of its therapeutic characteristics. A significant element that is anticipated to increase the manufacture of CBD-infused goods is the increased acceptance and use of products as a result of regulatory approvals.
• More and more skincare products that treat acne and wrinkles contain cannabidiol oil. For instance, Sephora recently added a line of CBD-infused beauty products to its retail locations. Similar to this, Ulta Beauty plans to introduce a range of products based on cannabidiol. Additionally, a number of new businesses are entering the market for cosmetics containing cannabidiol. For instance, the German market for the Aphria cannabidiol-based cosmetics line was opened in 2019. Aphria is a Canadian producer and distributor of medical and recreational cannabis.
• The COVID-19 epidemic, on the other hand, has brought about massive lockdowns throughout the world, causing daily operations to collapse and altering consumer behaviour in almost every industry. Retail establishments have closed while COVID-19 reaction efforts intensify. Due to the statewide suspension of transportation and manufacture in significant raw material-producing nations like China and India, the industry began to experience a supply deficit. Additionally, the availability of additional raw materials has been restricted as a result of supply chain disruptions in the U.S., which is impacting manufacturing and, consequently, the supply chain of CBD consumer health products.
• Cannabidiol is the cannabinoid most frequently utilized for therapeutic purposes because it has no psychoactive side effects. Cannabidiol oil is utilized in numerous medical procedures, including treating anxiety & depression, stress reduction, diabetes prevention, pain relief, cancer symptom relief, and inflammation. The global market is predicted to expand at a profitable rate throughout the forecast period as a result of the growing use of CBD-based products to cure illnesses.

Report Scope

The global CBD Product market research report offers an in-depth analysis of the global market size, which is further segmented into the regional and country-level market size, and segmentation market growth. Also, it provides the market share, sales analysis, competitive landscape, the impact of domestic and global market participants, trade regulations, value chain optimization, recent key developments, strategic market growth analysis, opportunities analysis, product launches, and technological innovations. The scope of the study includes market sizing and forecast for segmentation by source, distribution channel, application, and geography.

Key Market Dynamics

• Due to its medicinal properties, cannabidiol (CBD) is in high demand for health and wellness-related reasons, which is a key factor driving the global CBD product market expansion. Furthermore, the development of CBD-infused products is anticipated to be encouraged by improved product acceptance and use as a result of governmental approvals.
• A customer has decided to acquire cannabidiol products despite their high price because of the public's rising awareness of CBD's therapeutic potential. Commercial retailers are now concentrating on promoting products made from cannabis since they have a better profit margin.
• As a result of epilepsy and other pertinent diseases, seizures are thought to benefit significantly from the therapeutic effects of CBD. Clinical trials on CBD have also demonstrated its effectiveness in treating different types of epilepsy. On the basis of this breakthrough, nations are attempting to include CBD-based treatments, which will greatly increase demand.
• Additionally, cannabidiol heals haemorrhoids, lowers psychotic episodes linked to schizophrenia, and stops cramping throughout the menstrual cycle. Leading CBD firms promote it as a therapeutic component with "no side effects," making it a viable substitute for THC (Tetrahydrocannabinol).
• THC and cannabidiol both have effects on the immune system and the central nervous system (CNS), respectively. However, cannabidiol and THC work better together when mixed in equal proportions, providing an "entourage" effect that could influence how the cannabidiol sector develops in the future.
• Due to its anti-anxiety effects, cannabidiol is increasingly being used outside of pharmaceuticals, including as a component in sodas, mocktails, restaurants, and breweries.

The Pharmaceuticals Segment Dominated the CBD Product Market in 2021

• In 2021, the pharmaceuticals sub-segment led the CBD product market with a revenue share of more than 70.0%. Over the projection period, the segment is anticipated to expand at a profitable rate.
• Demand for products is expected to rise in the next years as a result of the growing number of trials that are now being conducted to examine the effects of CBD on specific health issues.
• Furthermore, many businesses create CBD-infused items after purchasing CBD oils in bulk. A sizable consumer base uses these items as an option for pain and stress management. As a result, the majority of these products are shown to be in the market's growth phase.
• Over the forecast period, the pharmaceuticals segment is anticipated to develop at the fastest rate. It is projected that the market will expand more quickly as a result of the rapidly evolving transition of cannabidiol from natural remedies to prescription medications. In the pharmaceutical sector, it is also projected that rising consumer demand would be driven by greater knowledge of cannabidiol's therapeutic effects.

Competitive Landscape

Customers can purchase products that deliver cannabidiol's advantages without getting high. As a result, they are quickly gathering momentum. The fact that businesses are concentrating on expanding their product offerings, entering new areas, and attracting new customers has also increased competitiveness in the global CBD industry. Due to the presence of numerous firms, the market is fragmented. In order to maintain their place in the industry, numerous businesses are introducing cutting-edge items and growing their presence in various regions. Additionally, businesses are forming numerous alliances to broaden their customer bases and distribution networks.

• 2021: Greenheart CBD, an Irish Company, became the first CBD producer to introduce a decentralized financial token. The token will help the business grow and give token holders access to affordable goods.
• 2021: Through pharmaceutical-grade cannabidiol branding services, Nano Hydrate has provided product marketing services that use cutting-edge technologies to promote natural treatments. It aimed to create a cooperative program that would expand the opportunities for cannabis-infused beverages while also enabling them to introduce established brands to the specialized CBD product market.

List of the prominent players in the global CBD Product market:

• INSYS Therapeutics Inc.
• EPIDIOLEX
• SolMic GmbH
• ENDOCA
• Folium Biosciences
• Cannoid LLC
• Marijuana Company of America Inc.
• Pivot Pharmaceuticals Inc.
• HoneyB Healthy
• NuLeaf Naturals LLC
• Nightfood Holdings
• Medical Marijuana Inc.
• Pharmahemp d.o.o.
• Isodiol International Inc.
• Others

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America